Poster Abstract Session:
249. Treatment of HAIs/Antimicrobial Resistant Infections
Saturday, October 10, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:


Tracks: Adult ID, Epidemiology and Infection Control

Antifungal resistance in England: results from national surveillance of invasive mycoses
Rebecca Guy, BSc (Hons) ; Theresa Lamagni, MSc PhD HonMFPH ; Berit Muller-Pebody, PhD
  • poster_1825_RG.pdf (681.6 kB)
  • In Vitro Activity of Colistin (Polymyxin E) Versus 2541 Pseudomonas aeruginosa Clinical Isolates Obtained from Patients in Canadian Hospitals: Results of the CANWARD Study, 2008-2014
    Andrew Walkty, MD ; Heather J. Adam, PhD ; Melanie Baxter, MSc ; Philippe Lagace-Wiens, MD ; James Karlowsky, PhD ; Daryl Hoban, PhD ; George Zhanel, PhD
  • IDSA 2015 P-1827.pdf (188.1 kB)
  • In Vitro Effect of Different Antimicrobial Colistin Based Regimens in Biofilm Production Strains of MDR A baumannii.
    César Emmanuel Lopez, Infectious Disease Resident ; Patricia Rodriguez Zulueta, Internal Medicine Physician ; Rigoberto Hernández Castro, PhD
    Antimicrobial Susceptibility of Carbapenem-Susceptible and -Resistant Acinetobacter baumannii (Ab): PRIMERS-III, part 1
    Michael R. Jacobs, MD, PhD ; Andrea Hujer, BS ; Kristine M. Hujer, BS ; Barry N. Kreiswirth, PhD ; Claudia Manca, PhD ; Liang Chen, PhD ; Robert A. Bonomo, MD
    Correlation of In Vitro Combination Antimicrobial Drug Therapy with Clinical Outcomes Among Extensively Drug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa
    Derek Bremmer, PharmD ; Karri a. Bauer, PharmD BCPS ; Stephanie Pouch, MD ; Keelie Thomas, n/a ; Preeti Pancholi, PhD ; Joan-Miquel Balada-Llasat, PharmD, PhD
    Comparison of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-tazobactam (PTZ) Extended Infusion (EI) versus Standard Infusion (SI)
    Mariam Mousavi, PharmD ; Tanya Zapolskaya, PharmD ; Marco R. Scipione, PharmD ; Eddie Louie, MD ; John Papadopoulos, PharmD ; Yanina Dubrovskaya, PharmD
  • CDI IDSA Poster 09282015.pdf (269.5 kB)
  • Clinical Outcomes of Ceftolozane/tazobactam Treatment of Piperacillin/tazobactam and Ceftazidime Non-Susceptible Pathogens from Two Phase 3 Trials and Associated In Vitro Activity
    Myra Popejoy, PharmD ; Eliana Armstrong, PhD ; Benjamin Miller, PharmD ; Jennifer Huntington, PharmD ; Patricia Bernardo, ScD ; Judith Steenbergen, PhD ; David J. Farrell, PhD ; Ellie Hershberger, PharmD
    Clinical and Economic Burden of Hospitalized Patients with Serious Infections due to Carbapenem Resistant Enterobacteriaceae (CRE)
    Rosa Wang, MHA ; Thomas Lodise, PharmD, PhD ; Tarun Bhagnani, MS ; Qi Zhao, MD, MPH ; Sharvari Bhurke, MS ; Ariel Berger, MPH
    Colistin Resistance in Patients with Carbapenem-resistant Klebsiella pneumoniae is Associated with Increased Mortality
    Madiha Salim, MD ; Federico Perez, MD ; Eric Cober, MD ; Sandra S. Richter, MD, FIDSA ; Robert Kalayjian, MD ; Robert Salata, MD, FIDSA ; Nikole Scalera, MD, MS ; Richard R. Watkins, MD, MS, FACP ; Yohei Doi, MD, PhD ; Scott Evans, PhD, MS ; Vance G. Fowler Jr., MD ; Robert Bonomo, MD ; Keith Kaye, MD, MPH, FIDSA, FSHEA ; David Van Duin, MD, PhD
    Unit-specific Pharmacodynamic Modelling to Aid in Empiric Therapy Selection
    W. Cliff Rutter, PharmD ; Donna R. Burgess, RPh ; David S. Burgess, PharmD, FCCP
  • MCS poster FINAL.pdf (580.2 kB)
  • The effect of inadequate initial antimicrobial treatment on mortality in critically ill patients with bloodstream infections
    Rachel Savage, MSc ; Robert Fowler, MD, MSc ; Sean Bagshaw, MD, MSc ; Deborah Cook, MD, MSc ; Peter Dodek, MD, MHSc ; Richard Hall, MD ; Anand Kumar, MD ; François Lamontagne, MD ; François Lauzier, MD, MSc ; John Marshall, MD ; Claudio Martin, MD, MSc ; Lauralyn Mcintyre, MD, MSc ; John Muscedere, MD ; Steven Reynolds, MD ; Asgar Rishu, MBBS ; Tom Stelfox, MD, PhD ; Nick Daneman, MD, MSc
    Ceftaroline as Salvage Therapy for Methicillin-Resistant Staphylococcus aureus Infection: A Case Series
    Ellie Sukerman, MD ; Michael Angarone, DO ; John Esterly, PharmD ; Sarah Sutton, MD ; Teresa Zembower, MD, MPH, FIDSA
    Ceftaroline (CF) for Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia, Endocarditis and Other Deep Seated Infections
    Gemma Berlanga, MD ; Alan Howell, MD ; Janice Koshy, MD ; Karen Brust, MD ; John Midturi, DO ; Lizbeth Cahuayme-Zuniga, MD
  • CF poster-MV.pdf (1.0 MB)
  • Correlation of antibiotic exposure with the development of Daptomycin non-susceptible enterococcus (DNSE) and linezolid non-susceptible enterococcus (LNSE) isolates at a tertiary care center
    David Truong, M.D. ; Jan Zakrzewski, M.D. ; Shelley Kon, M.D. ; Gayle Balba, M.D. ; Richard Teran, MPH ; Lan Duong, PharmD ; Princy Kumar, M.D. ; Steven Ajluni, B.S. ; Joseph Timpone, M.D.
    Analysis of Telavancin in vitro Activity Tested Against a USA Collection of Staphylococcus aureus Clinical Isolates Causing Hospital-acquired Pneumonia (2013-2014)
    Rodrigo E. Mendes, PhD ; Helio S. Sader, MD, PhD ; Robert K. Flamm, PhD ; Jennifer I. Smart, PhD ; David J. Farrell, PhD ; Ronald N. Jones, MD
    All-Cause Readmission Following Treatment with Linezolid for MRSA-ABSSSI: A Propensity Score Analysis
    Emily T. Martin, MPH, PhD ; Richard Evans, BS ; Matthew Compton, . ; Jason Pogue, PharmD ; Paul Lephart, PhD ; Michael J Rybak, PharmD, MPH ; Keith Kaye, MD, MPH, FIDSA, FSHEA ; Susan L Davis, PharmD
    Beta-Lactam Specific Antibiogram of Daptomycin Susceptible (DSSA) and Non-Susceptible Staphylococcus aureus (DNSA) Isolates
    Christopher Wilming, Pharm.D. candidate ; Mena Raouf, Pharm.D. candidate ; Karina Petrovets, Pharm.D. candidate ; John Tremblay, BS ; Steven Lane, MS ; Anthony M. Nicasio, PharmD
    Clinical Characteristics and Patient Outcomes Associated with Daptomcyin non-susceptible Enterococcus (DNSE) and Linezolid non-susceptible Enterococcus (LNSE)
    Shelley Kon, M.D. ; David Truong, M.D. ; Jan Zakrzewski, M.D. ; Gayle Balba, M.D. ; Richard Teran, MPH ; Brett Toimil, B.A. ; Lan Duong, PharmD ; Princy Kumar, M.D. ; Joseph Timpone, M.D.
  • DNSE and LNSE.pdf (943.6 kB)
  • Daptomycin-Beta-lactam Combination Therapy of Experimental Methicillin Resistant Staphylococcus aureus Endocarditis
    Henry Chambers, MD, FIDSA ; Li Basuino, MS ; Stephanie Hamilton, PhD ; Eun Ju Choo, MD, PhD ; Pamela Moise, PharmD
    Survey of Clostridium difficile Prescribing Practices for Hematology/Oncology Patients
    Laura Gleason, PharmD ; Susanne Liewer, PharmD, BCOP ; Kiri Rolek, PharmD, BCPS ; Donald Klepser, PhD, MBA ; Alison G. Freifeld, MD
    Earlier Use of Vancomycin Taper and Pulse (VAN-TP) is More Effective for Managing Clostridium difficile Infection (CDI) Recurrences
    Melinda Soriano, PharmD, BCPS ; Carl Manzo, MD ; Dale Gerding, MD, FIDSA ; Stuart Johnson, MD, FIDSA
  • VAN TP ID Week 2015.pdf (235.1 kB)
  • CME Credits:

    ACPE Credits:

    ACPE Number:

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.